Anti-MMP9 [2C3]
Invented by Ayham Alnabulsi from Vertebrate Antibodies Limited
Invented at Vertebrate Antibodies Limited
- Datasheet
- References (14)
- Inventor Info
Info
![Image thumbnail for Anti-MMP9 [2C3]](https://res.cloudinary.com/ximbio/image/upload/c_fit,fl_lossy,h_45,q_auto/11363949-f270-4471-95cb-741450e239f5.jpg)
![Image thumbnail for Anti-MMP9 [2C3]](https://res.cloudinary.com/ximbio/image/upload/c_fit,fl_lossy,h_45,q_auto/1dda0a3b-09f3-41f5-a78c-36db6740dcf3.jpg)
| Catalogue Number | 151621 |
| Applications | IHC IF IP WB |
| Antigen/Gene or Protein Targets | Human matrix metalloproteinase 9 (MMP-9) |
| Reactivity | Human |
| Relevance |
Matrix metalloproteinase (MMP) family are involved in the breakdown of extracellular matrix (ECM) in normal physiological processes as well as in disease processes. Tissue inhibitors of metalloproteinases (TIMPs) are the main physiological regulators of the MMPs. The TIMPs are secreted proteins that complex with individual MMPs and regulate the activity of specific MMPs. Together, the MMPs and TIMPs form a complex biological system strictly controlling degradation of ECM. The MMPs and TIMPs have a significant role in facilitating tumour invasion and metastasis. Expression of MMP9 has been identified in individual studies as prognostic biomarkers in established and locally advanced colorectal cancer. |
| Host | Mouse |
| Immunogen | Ovalbumin-conjugated synthetic peptide; KLGLGADVAQVT |
| Positive Control | IHC: formalin-fixed, paraffin-embedded lung containing intra-alveolar macrophage. Western Blot: rhMMP-9, 400 ng per lane |
| Subclass | IgG1 kappa |
| Myeloma Used | P3X63Ag8.653 |
| Recommended Growing Conditions | Dulbecco’s media containing L-Glutamine and 20% Fetal Bovine serum (DH20) . |
| Strain | Balb/c |
| Notes |
IHC: a recommended dilution of 1/32 and pretreatment of antigen retrieval: microwave for 10 minutes at 950W in 0.01M sodium citrate buffer, pH 6.0. Western Blot: not reactive with MMP-1, -2, -3. A recommended dilution of 1/5. |
| Research Area | Adhesion, Cancer, Cardiovascular, Epigenetics & Nuclear Signalling |
References: 14 entries
Sreekanth et al. 2011. Oncogene. 30(28):3139-52. PMID: 21317920.
Molecular evidences for the chemosensitizing efficacy of liposomal curcumin in paclitaxel chemotherapy in mouse models of cervical cancer.
Europe PMC ID: 21317920
Jeffery et al. 2009. Histopathology. 54(7):820-8. PMID: 19635101.
The matrix metalloproteinase/tissue inhibitor of matrix metalloproteinase profile in colorectal polyp cancers.
Europe PMC ID: 19635101
Lyall et al. 2006. Clin Cancer Res. 12(4):1184-91. PMID: 16489072.
Profiling markers of prognosis in colorectal cancer.
Europe PMC ID: 16489072
Curran et al. 2004. Clin Cancer Res. 10(24):8229-34. PMID: 15623598.
Matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis colorectal cancers.
Europe PMC ID: 15623598
Murray et al. 1998. Gut. 43(6):791-7. PMID: 9824606.
Matrix metalloproteinases and their inhibitors in gastric cancer.
Europe PMC ID: 9824606
Duncan et al. 1998. Eur J Biochem. 258(1):37-43. PMID: 9851689.
Human matrix metalloproteinase-9: activation by limited trypsin treatment and generation of monoclonal antibodies specific for the activated form.
Europe PMC ID: 9851689
Murray et al. 1998. J Pathol. 185(3):256-61. PMID: 9771478.
Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer.
Europe PMC ID: 9771478
Add a reference
References: 14 entries
Sreekanth et al. 2011. Oncogene. 30(28):3139-52. PMID: 21317920.
Molecular evidences for the chemosensitizing efficacy of liposomal curcumin in paclitaxel chemotherapy in mouse models of cervical cancer.
Jeffery et al. 2009. Histopathology. 54(7):820-8. PMID: 19635101.
The matrix metalloproteinase/tissue inhibitor of matrix metalloproteinase profile in colorectal polyp cancers.
Lyall et al. 2006. Clin Cancer Res. 12(4):1184-91. PMID: 16489072.
Profiling markers of prognosis in colorectal cancer.
Curran et al. 2004. Clin Cancer Res. 10(24):8229-34. PMID: 15623598.
Matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis colorectal cancers.
Murray et al. 1998. Gut. 43(6):791-7. PMID: 9824606.
Matrix metalloproteinases and their inhibitors in gastric cancer.
Duncan et al. 1998. Eur J Biochem. 258(1):37-43. PMID: 9851689.
Human matrix metalloproteinase-9: activation by limited trypsin treatment and generation of monoclonal antibodies specific for the activated form.
Murray et al. 1998. J Pathol. 185(3):256-61. PMID: 9771478.
Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer.
Add a reference
